Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Refractory/Relapse Neuroblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Lung Neoplasms 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 5Nivolumab 3Cisplatin 3Taxes 2Paclitaxel 2poly ICLC 1fludarabine phosphate 1fludarabine 1abemaciclib 1Risk Factors 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Pemetrexed 1Nimorazole 1Injections 1High-Intensity Focused Ultrasound Ablation 1Erlotinib Hydrochloride 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Biological Products 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Biological Products × 1 year × Clear all
NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Cancer Research UK

Phase 1/2 Suspended
15 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡